173 related articles for article (PubMed ID: 33430709)
1. Exploring of paritaprevir and glecaprevir resistance due to A156T mutation of HCV NS3/4A protease: molecular dynamics simulation study.
Boonma T; Nutho B; Darai N; Rungrotmongkol T; Nunthaboot N
J Biomol Struct Dyn; 2022 Aug; 40(12):5283-5294. PubMed ID: 33430709
[TBL] [Abstract][Full Text] [Related]
2.
Ng TI; Tripathi R; Reisch T; Lu L; Middleton T; Hopkins TA; Pithawalla R; Irvin M; Dekhtyar T; Krishnan P; Schnell G; Beyer J; McDaniel KF; Ma J; Wang G; Jiang LJ; Or YS; Kempf D; Pilot-Matias T; Collins C
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084747
[TBL] [Abstract][Full Text] [Related]
3. Molecular and Structural Mechanism of Pan-Genotypic HCV NS3/4A Protease Inhibition by Glecaprevir.
Timm J; Kosovrasti K; Henes M; Leidner F; Hou S; Ali A; Kurt Yilmaz N; Schiffer CA
ACS Chem Biol; 2020 Feb; 15(2):342-352. PubMed ID: 31868341
[TBL] [Abstract][Full Text] [Related]
4. Understanding of the drug resistance mechanism of hepatitis C virus NS3/4A to paritaprevir due to D168N/Y mutations: A molecular dynamics simulation perspective.
Boonma T; Nutho B; Rungrotmongkol T; Nunthaboot N
Comput Biol Chem; 2019 Dec; 83():107154. PubMed ID: 31751885
[TBL] [Abstract][Full Text] [Related]
5. Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis.
Xue W; Ban Y; Liu H; Yao X
J Chem Inf Model; 2014 Feb; 54(2):621-33. PubMed ID: 23745769
[TBL] [Abstract][Full Text] [Related]
6. Low susceptibility of asunaprevir towards R155K and D168A point mutations in HCV NS3/4A protease: A molecular dynamics simulation.
Kammarabutr J; Mahalapbutr P; Nutho B; Kungwan N; Rungrotmongkol T
J Mol Graph Model; 2019 Jun; 89():122-130. PubMed ID: 30884449
[TBL] [Abstract][Full Text] [Related]
7. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors.
Romano KP; Ali A; Aydin C; Soumana D; Ozen A; Deveau LM; Silver C; Cao H; Newton A; Petropoulos CJ; Huang W; Schiffer CA
PLoS Pathog; 2012; 8(7):e1002832. PubMed ID: 22910833
[TBL] [Abstract][Full Text] [Related]
8. Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants.
Jensen SB; Fahnøe U; Pham LV; Serre SBN; Tang Q; Ghanem L; Pedersen MS; Ramirez S; Humes D; Pihl AF; Filskov J; Sølund CS; Dietz J; Fourati S; Pawlotsky JM; Sarrazin C; Weis N; Schønning K; Krarup H; Bukh J; Gottwein JM
Hepatology; 2019 Sep; 70(3):771-787. PubMed ID: 30964552
[TBL] [Abstract][Full Text] [Related]
9. Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors.
Dultz G; Shimakami T; Schneider M; Murai K; Yamane D; Marion A; Zeitler TM; Stross C; Grimm C; Richter RM; Bäumer K; Yi M; Biondi RM; Zeuzem S; Tampé R; Antes I; Lange CM; Welsch C
J Biol Chem; 2020 Oct; 295(40):13862-13874. PubMed ID: 32747444
[TBL] [Abstract][Full Text] [Related]
10. Exploring resistance mechanisms of HCV NS3/4A protease mutations to MK5172: insight from molecular dynamics simulations and free energy calculations.
Guan Y; Sun H; Pan P; Li Y; Li D; Hou T
Mol Biosyst; 2015 Sep; 11(9):2568-78. PubMed ID: 26219385
[TBL] [Abstract][Full Text] [Related]
11. Understanding the structural and energetic basis of inhibitor and substrate bound to the full-length NS3/4A: insights from molecular dynamics simulation, binding free energy calculation and network analysis.
Xue W; Wang M; Jin X; Liu H; Yao X
Mol Biosyst; 2012 Oct; 8(10):2753-65. PubMed ID: 22833015
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir.
Schnell G; Krishnan P; Tripathi R; Beyer J; Reisch T; Irvin M; Dekhtyar T; Lu L; Ng TI; Xie W; Pilot-Matias T; Collins C
PLoS One; 2018; 13(10):e0205186. PubMed ID: 30286205
[TBL] [Abstract][Full Text] [Related]
13. Deciphering the Molecular Mechanism of HCV Protease Inhibitor Fluorination as a General Approach to Avoid Drug Resistance.
Zephyr J; Nageswara Rao D; Vo SV; Henes M; Kosovrasti K; Matthew AN; Hedger AK; Timm J; Chan ET; Ali A; Kurt Yilmaz N; Schiffer CA
J Mol Biol; 2022 May; 434(9):167503. PubMed ID: 35183560
[TBL] [Abstract][Full Text] [Related]
14. Computational study on the molecular mechanisms of drug resistance of Narlaprevir due to V36M, R155K, V36M+R155K, T54A, and A156T mutations of HCV NS3/4A protease.
Wang H; Geng L; Chen BZ; Ji M
Biochem Cell Biol; 2014 Oct; 92(5):357-69. PubMed ID: 25178998
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of interactions between the hepatitis C virus NS3/4A and sulfonamidobenzamide based molecules using molecular docking, molecular dynamics simulations and binding free energy calculations.
Ren J; Vaid TM; Lee H; Ojeda I; Johnson ME
J Comput Aided Mol Des; 2023 Jan; 37(1):53-65. PubMed ID: 36427108
[TBL] [Abstract][Full Text] [Related]
16. Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K, A156V and D168A to TMC435.
Xue W; Pan D; Yang Y; Liu H; Yao X
Antiviral Res; 2012 Jan; 93(1):126-37. PubMed ID: 22127068
[TBL] [Abstract][Full Text] [Related]
17. Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors.
Matthew AN; Zephyr J; Nageswara Rao D; Henes M; Kamran W; Kosovrasti K; Hedger AK; Lockbaum GJ; Timm J; Ali A; Kurt Yilmaz N; Schiffer CA
mBio; 2020 Mar; 11(2):. PubMed ID: 32234812
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice.
Teraoka Y; Uchida T; Imamura M; Osawa M; Tsuge M; Abe-Chayama H; Hayes CN; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K;
Biochem Biophys Res Commun; 2018 Jun; 500(2):152-157. PubMed ID: 29621544
[TBL] [Abstract][Full Text] [Related]
19. Effect of D168V mutation in NS3/4A HCV protease on susceptibilities of faldaprevir and danoprevir.
Meeprasert A; Hannongbua S; Kungwan N; Rungrotmongkol T
Mol Biosyst; 2016 Nov; 12(12):3666-3673. PubMed ID: 27731877
[TBL] [Abstract][Full Text] [Related]
20. [Molecular recognition mechanism and motion of HCV NS3/4A protease with Faldaprevir analogue].
Liang L; Hu J; Du W; Zuo K; Liu W; Gou X
Sheng Wu Gong Cheng Xue Bao; 2016 May; 32(5):669-682. PubMed ID: 29019204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
